RDHL — Redhill Biopharma Balance Sheet
0.000.00%
- $4.01m
- $1.36m
- $8.04m
- 63
- 46
- 20
- 38
Annual balance sheet for Redhill Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 6-K | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 29.8 | 38 | 20 | 5.57 | 4.62 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 28.7 | 31.7 | 34.5 | 2.59 | 2.54 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 70.5 | 89.2 | 85.9 | 16.1 | 11.9 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.7 | 4.22 | 7.19 | 1.18 | 0.437 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 180 | 181 | 159 | 23 | 18 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 73.2 | 81.5 | 197 | 20 | 22.2 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 166 | 172 | 207 | 21 | 22.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 13.9 | 8.88 | -48.4 | 2.07 | -4.68 |
| Total Liabilities & Shareholders' Equity | 180 | 181 | 159 | 23 | 18 |
| Total Common Shares Outstanding |